TM
RCKT icon

Tiger Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Tiger Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-279,700
Closed -$5.47M – 38
2022
Q4 		$5.47M Hold
279,700
– – 2.07% 14
2022
Q3 		$4.46M Buy
+279,700
New +$4.36M 1.95% 14

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Tiger Management's RCKT Position: Q1 2023 in Review

Tiger Management sold out of Rocket Pharmaceuticals (RCKT) in Q1 2023, closing a stake of 279,700 shares — an estimated $5.47M sold.

Tiger Management first reported a position in RCKT in Q3 2022 and held it in 2 quarters. The position peaked at $5.47M in Q4 2022. 163 funds tracked by Wall St. Rank hold RCKT as of Q1 2023.

  • Tiger Management reported no remaining Rocket Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Tiger Management sold 279,700 Rocket Pharmaceuticals shares in Q1 2023, an estimated $5.47M.
  • Tiger Management first reported a position in Rocket Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Tiger Management's Rocket Pharmaceuticals position peaked at $5.47M in Q4 2022.
  • 163 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2023.

Based on Tiger Management's 13F filing for Q1 2023, filed 15 May 2023.